Vasgene Therapeutics Inc is categorized under Commercial Medical Research in Los Angeles, CA and active since 1998.
Vasgene Therapeutics Inc was established in 1998, and today employs 1 to 4, earning Unknown per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 5417114 by the NAICS.
If you are seeking more information, feel free to contact P Gill, President at the company’s single location by writing to 1929 Zonal Avenue, Los Angeles, California CA 90033 or by phoning (323) 221-7818. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Vasgene Therapeutics Inc |
| Contact Person: | P Gill, President |
| Address: | 1929 Zonal Avenue, Los Angeles, California 90033 |
| Phone Number: | (323) 221-7818 |
| Website Address: | vasgene.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 1998 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5417114 |
| Share This Business: |
Vasgene Therapeutics Inc was started in 1998 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 5417114. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact P Gill, President for inquiries that concern Vasgene Therapeutics Inc by calling the company number (323) 221-7818, as your correspondence is most welcome. Additionally, the physical location of the single location of Vasgene Therapeutics Inc can be found at the coordinates 34.06066,-118.20737 as well as the street address 1929 Zonal Avenue in Los Angeles, California 90033.
For its online presence, you may visit Vasgene Therapeutics Inc’s website at vasgene.com and engage with its social media outlets through on Twitter and on Facebook.